WES  PC9 cells
Whole-exome sequencing was performed in order to identify somatic mutations in the coding regions of the human genome. Following a quantitative-PCR-based DNA quality and quantity assessment using the Agilent NGS FFPE QC Kit, 200ng of DNA was used as input into the Agilent SureSelect XT Clinical Research Exome kit, which includes the exon targets of Agilents v5 whole-exome kit, with increased coverage at 5000 disease-associated targets (Agilent Technologies, Santa Clara, CA).  Briefly, for each tumor DNA sample, a genomic DNA library was constructed according to the manufacturers protocol and the size and quality of the library was evaluated using the Agilent BioAnalyzer.  An equimolar amount of library DNA was used for a whole-exome enrichment using the Agilent capture baits and after quantitative PCR library quantitation and QC analysis on the BioAnalyzer, approximately 100 million 75-base paired-end sequences per sample were generated using v2 chemistry on an Illumina NextSeq 500 sequencer (Illumina, Inc., San Diego, CA)